What it sells
mRNA therapeutics to extend healthspan entering clinical trials
Business model breakdown
Buyer: who owns the budget?
UnverifiedEventual payers: health systems/insurers via drug approval; near-term funders are investors and grant agencies.
Workflow: what inputs become what output?
Proprietary therapeutic telomere extension (mRNA) to lengthen telomeres in specific cells; claims 5+ years of telomere shortening reversed in 1 day in cells; targeting diseases such as pulmonary fibrosis, liver disease and bone marrow failure.
Economics: what it saves and how it charges
Pre-revenue biotech funded by equity and grants: claims over $8M in grant funding awarded since 2023 and over 40 patents granted.
Distribution: how it reaches customers
UnverifiedTherapeutic pipeline route: clinical trials then regulatory approval and likely pharma partnering; no commercial channel yet.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.